We are live on ! Find out more
SI

Sofinnova Investments Portfolio holdings

AUM $2.63B
1-Year Est. Return 117.41%
This Fund
S&P 500
This Quarter Est. Return
-4.77%
1 Year Est. Return
+117.41%
3 Year Est. Return
+428.82%
5 Year Est. Return
+748.21%
10 Year Est. Return
–
AUM
$1.53B
AUM Growth
+$158M
Cap. Flow
+$341M
Cap. Flow %
22.28%
Top 10 Hldgs %
52.34%
Holding
81
New
20
Increased
20
Reduced
13
Closed
17

Top Buys

Rank Stock Value
1
SYK icon
Stryker
SYK
+$69.5M
2
MDT icon
Medtronic
MDT
+$50.4M
3
IDYA icon
IDEAYA Biosciences
IDYA
+$33.1M
4
LLY icon
Eli Lilly
LLY
+$32M
5
PTCT icon
PTC Therapeutics
PTCT
+$28.9M

Top Sells

Rank Stock Value
1
ABBV icon
AbbVie
ABBV
+$63.9M
2
AZN icon
AstraZeneca
AZN
+$42.7M
3
GILD icon
Gilead Sciences
GILD
+$36.7M
4
AXSM icon
Axsome Therapeutics
AXSM
+$36M
5
BSX icon
Boston Scientific
BSX
+$31M

Sector Composition

Rank Sector Weight
1 Healthcare 86.61%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SRPT icon
26
Sarepta Therapeutics
SRPT
$1.66B
$20.9M 1.37%
327,618
-101,153
-24% -$10.6M
AKRO
27
DELISTED
Akero Therapeutics
AKRO
$20.6M 1.35%
+510,020
New +$21.6M
AXSM icon
28
Axsome Therapeutics
AXSM
$12.4B
$20.4M 1.34%
175,317
-316,409
-64% -$36M
RAPP
29
Rapport Therapeutics
RAPP
$1.95B
$20M 1.31%
1,995,594
– –
SUPN icon
30
Supernus Pharmaceuticals
SUPN
$2.68B
$17.1M 1.11%
+520,678
New +$18.5M
SVRA icon
31
Savara
SVRA
$1.13B
$15.2M 0.99%
5,481,666
+10,367
+0.2% +$28.6K
COGT icon
32
Cogent Biosciences
COGT
$6.79B
$13.1M 0.85%
2,182,121
+1,358,961
+165% +$10.7M
ROIV icon
33
Roivant Sciences
ROIV
$25.2B
$12.9M 0.84%
+1,279,510
New +$13.8M
DHR icon
34
Danaher
DHR
$135B
$12M 0.78%
58,606
+48,606
+486% +$10.6M
PEN icon
35
Penumbra
PEN
$12.5B
$11.5M 0.75%
+42,936
New +$11.6M
RNAM
36
DELISTED
Avidity Biosciences
RNAM
$11.2M 0.73%
379,931
+366,142
+2,655% +$11.4M
INBX icon
37
Inhibrx
INBX
$1.2B
$9.76M 0.64%
697,916
+170,726
+32% +$2.32M
YMAB
38
DELISTED
Y-mAbs Therapeutics
YMAB
$9.72M 0.63%
2,194,278
– –
JBIO
39
Jade Biosciences
JBIO
$1.22B
$9.43M 0.62%
107,391
– –
PHVS icon
40
Pharvaris
PHVS
$2.39B
$9.32M 0.61%
593,403
+32,680
+6% +$551K
BIOA
41
BioAge Labs
BIOA
$968M
$8.67M 0.57%
2,304,901
– –
ACAD icon
42
CALL
Acadia Pharmaceuticals
ACAD
$4.25B
$8.3M 0.54%
+500,000
New +$9.08M
RCUS icon
43
Arcus Biosciences
RCUS
$3.57B
$8.15M 0.53%
+1,037,776
New +$12M
EWTX icon
44
Edgewise Therapeutics
EWTX
$4.39B
$7.53M 0.49%
342,218
-60,555
-15% -$1.59M
DYN icon
45
Dyne Therapeutics
DYN
$4.04B
$7.5M 0.49%
716,896
-354,602
-33% -$5.07M
EWTX icon
46
PUT
Edgewise Therapeutics
EWTX
$4.39B
$7.05M 0.46%
+320,400
New +$8.41M
IMTX icon
47
Immatics
IMTX
$1.24B
$7.01M 0.46%
1,554,304
+1,211,098
+353% +$6.32M
PRAX icon
48
Praxis Precision Medicines
PRAX
$9.07B
$5.97M 0.39%
+157,640
New +$9.84M
ISRG icon
49
Intuitive Surgical
ISRG
$121B
$5.94M 0.39%
11,984
-25,912
-68% -$14.3M
QURE icon
50
uniQure
QURE
$2.68B
$5.79M 0.38%
+545,771
New +$7.65M
1
2
3 4

Similar funds

WWM
Western Wealth Management Golden, Colorado $2.63B AUM 21.3% 1-Year Est. Return
ACI
Amazon.com Inc Seattle, Washington $2.63B AUM 20.53% 1-Year Est. Return
LOAMS
Lombard Odier Asset Management (Switzerland) Petit-Lancy, Switzerland $2.63B AUM 31.52% 1-Year Est. Return
IA
Integrity Alliance Urbandale, Iowa $2.64B AUM 16.75% 1-Year Est. Return
WCA
Waratah Capital Advisors Toronto, Ontario, Canada $2.63B AUM 76.33% 1-Year Est. Return
ACM
Advance Capital Management Southfield, Michigan $2.64B AUM 13.57% 1-Year Est. Return
NIG
NFJ Investment Group Dallas, Texas $2.64B AUM 23.86% 1-Year Est. Return
WBG
Wharton Business Group Malvern, Pennsylvania $2.65B AUM 20.73% 1-Year Est. Return

Sofinnova Investments's Q1 2025 Portfolio in Review

As of Q1 2025, Sofinnova Investments held 81 positions worth $1.53B, up 12% from $1.37B the previous quarter. Its ten largest holdings account for 52% of the portfolio.

Sofinnova Investments deployed $341M of net new capital in Q1 2025, opening 20 new positions and adding to 20 existing holdings. Its largest new stake was Medtronic: 562,992 shares worth $50.6M.

By sector, the portfolio is most concentrated in Healthcare at 87% of assets, down from 99% a quarter earlier.

On the sell side, the largest reduction was Gilead Sciences, an estimated $36.7M trimmed.

  • Sofinnova Investments's largest Q1 2025 buy was Medtronic: 562,992 shares worth $50.6M.
  • Sofinnova Investments added most to Stryker in Q1 2025, an estimated $69.5M increase.
  • Sofinnova Investments's biggest Q1 2025 reduction was Gilead Sciences, cutting an estimated $36.7M.
  • Sofinnova Investments fully exited AbbVie in Q1 2025, selling an estimated $63.9M.
  • Sofinnova Investments's ten largest holdings make up 52% of its $1.53B portfolio in Q1 2025.
  • Sofinnova Investments opened 20 new positions and closed 17 in Q1 2025.
  • Sofinnova Investments's portfolio value rose 12% quarter-over-quarter to $1.53B.

Based on Sofinnova Investments's 13F filing for Q1 2025, filed 15 May 2025.